| Overview |
| bs-5725R-Cy5.5 |
| TNFSF13 Polyclonal Antibody, Cy5.5 Conjugated |
| FCM, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human |
| Mouse, Rat |
| Specifications |
| Cy5.5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human TNFSF13 |
| 21-120/250 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 8741 |
| Secreted |
| A proliferation inducing ligand; A proliferation-inducing ligand; APRIL; CD 256; CD256; CD256 antigen; Ligand; proliferation inducing ligand APRIL; TALL 2; TALL-2; TALL2; TNF and APOL related leukocyte expressed ligand 2; TNF related death ligand 1; TNF related death ligand; TNF- and APOL-related leukocyte expressed ligand 2; TNF-related death ligand 1; TNF13_HUMAN; TNFSF 13; TNFSF13; TNFSF13 protein; TRDL 1; TRDL-1; TRDL1; Tumor necrosis factor ligand superfamily member 13; Tumor necrosis factor ligand superfamily member 13; Tumor necrosis factor related death ligand; Tumor necrosis factor related death ligand 1; Tumor necrosis factor superfamily member 13; TWE PRIL; ZTNF2. |
| Cytokine that binds to TNFRSF13B/TACI and to TNFRSF17/BCMA. May be implicated in the regulation of tumor cell growth. May be involved in monocyte/macrophage-mediated immunological processes. |
| Application Dilution |
| FCM |
1:20-100 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz